Don’t let the high cost of brand specialty antiviral therapy disrupt your treatment. We help eligible patients access Vistide (cidofovir) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Vistide Prescription Assistance Program is a manufacturer-sponsored initiative that provides Vistide at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for AIDS-related CMV retinitis and other immunocompromised-host viral infections in patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, infectious disease/oncology/transplant provider coordination, prior-authorization documentation, infusion logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-coordination and re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$2,300/vial | Save substantially |
| CVS Pharmacy | ~$2,400/vial | Save substantially |
| Walmart | ~$1,900/vial | Save substantially |
| Costco | ~$1,850/vial | Save substantially |
Specialty Pharmacy | ~$2,000/vial | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Vistide at no medication cost if approved. Our $69.95/month service covers full advocacy.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Vistide:
Still $1,800–$2,400 per vial per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Vistide assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Vistide (cidofovir) is an intravenous nucleotide analog antiviral primarily used to treat CMV retinitis in adults with AIDS. It also has off-label uses for other DNA-virus infections (BK virus, adenovirus, HPV-related lesions, refractory HSV/VZV) in immunocompromised patients.
How Vistide Works:
Cidofovir functions by mimicking a building block of DNA to interfere with the replication of DNA viruses like CMV and HSV. Once inside a cell, it is converted into an active form that competes with natural components to join the viral DNA chain. This incorporation effectively blocks the chain from growing further, which halts the virus’s ability to copy its genome. It is highly effective against a wide range of DNA viruses but has no impact on RNA viruses.
Form and use:
Vistide is administered via intravenous infusion on a schedule of every one to two weeks. Because the drug can be hard on the kidneys, it must be given alongside IV saline hydration and specific doses of oral probenecid. Patients require consistent laboratory monitoring before every dose to check renal function, urine protein, neutrophil counts, and eye pressure.
Generic availability:
As of 2026, there is no generic version of cidofovir available in the United States. While Vistide remains an option, other antivirals like generic ganciclovir, valganciclovir, and foscarnet are often used, with valganciclovir typically serving as the first-line treatment for CMV retinitis. Brincidofovir was developed as an oral alternative with less kidney toxicity, but it currently has limited availability for HCMV.
Warnings:
Vistide carries several boxed warnings, most notably for severe and potentially fatal renal toxicity, making hydration and probenecid use mandatory. It can also cause neutropenia, eye-related issues like ocular hypotony, and is considered a possible carcinogen based on animal studies. The medication is strictly contraindicated for individuals with significant kidney impairment or those taking other drugs that could damage the kidneys.
Vistide costs approximately $1,800–$2,400 per 375 mg/5 mL vial. A treatment cycle (typically 5 mg/kg every 2 weeks for adults with CMV retinitis) commonly costs $7,000–$15,000+. Through AffordMyPrescriptions, qualifying patients receive Vistide at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Vistide is FDA-approved for CMV retinitis in adults with AIDS. It is also used off-label for other immunocompromised-host viral infections — BK virus nephropathy in kidney transplant patients, adenovirus disease in transplant patients, HPV-related severe lesions, and refractory HSV/VZV. The off-label uses are typically considered when first-line antivirals fail or are not appropriate
Cidofovir is highly nephrotoxic. Oral probenecid (a uricosuric agent) and IV saline pre-hydration substantially reduce kidney injury risk by competing with cidofovir for the active transport into kidney tubule cells. Both probenecid and pre-hydration are mandatory — Vistide should not be given without them.
For CMV retinitis induction, the typical dose is 5 mg/kg IV once weekly for 2 weeks. Maintenance dosing is then 5 mg/kg IV once every 2 weeks. Each infusion takes about 1 hour, plus pre-hydration and probenecid timing.
Yes. Medicare beneficiaries can typically qualify. Vistide is typically billed through Medicare Part B (provider-administered IV infusion), which covers most of the cost; the PAP can help with copays or for patients without insurance.
Renal injury is the most serious — kidney function is monitored before each dose, and the medication is held or stopped if creatinine rises. Neutropenia (low white blood cell counts) requires CBC monitoring. Ocular hypotony (low intraocular pressure) and uveitis can occur — eye exams are part of routine monitoring.
If denied, we explore alternatives — switching to generic tenofovir disoproxil fumarate or generic entecavir, the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
If you are struggling with the high cost of Vistide, our team may be able to help you access assistance programs designed to make brand specialty antivirals affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.